Literature DB >> 26648619

Empagliflozin.

.   

Abstract

Entities:  

Year:  2015        PMID： 26648619      PMCID： PMC4653997          DOI： 10.18773/austprescr.2015.024

Source DB:  PubMed          Journal:  Aust Prescr        ISSN： 0312-8008


× No keyword cloud information.
  6 in total

Review 1.  Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis.

Authors:  A Liakos; T Karagiannis; E Athanasiadou; M Sarigianni; M Mainou; K Papatheodorou; E Bekiari; A Tsapas
Journal:  Diabetes Obes Metab       Date:  2014-05-28       Impact factor: 6.577

2.  Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia.

Authors:  J Rosenstock; L J Seman; A Jelaska; S Hantel; S Pinnetti; T Hach; H J Woerle
Journal:  Diabetes Obes Metab       Date:  2013-08-22       Impact factor: 6.577

3.  Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial.

Authors:  Hans-Ulrich Häring; Ludwig Merker; Elke Seewaldt-Becker; Marc Weimer; Thomas Meinicke; Uli C Broedl; Hans J Woerle
Journal:  Diabetes Care       Date:  2014-04-10       Impact factor: 19.112

4.  Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial.

Authors:  Martin Ridderstråle; Knut Robert Andersen; Cordula Zeller; Gabriel Kim; Hans J Woerle; Uli C Broedl
Journal:  Lancet Diabetes Endocrinol       Date:  2014-06-16       Impact factor: 32.069

5.  Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Michael Roden; Jianping Weng; Jens Eilbracht; Bruno Delafont; Gabriel Kim; Hans J Woerle; Uli C Broedl
Journal:  Lancet Diabetes Endocrinol       Date:  2013-09-09       Impact factor: 32.069

6.  Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial.

Authors:  Hans-Ulrich Häring; Ludwig Merker; Elke Seewaldt-Becker; Marc Weimer; Thomas Meinicke; Hans J Woerle; Uli C Broedl
Journal:  Diabetes Care       Date:  2013-08-20       Impact factor: 19.112
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.